Last Updated: 02/12/2024
Efficient and Low-cost Malaria Vaccine using Plant Virus Nanoparticles
Objectives
The project team sought to determine whether using Papaya mosaic virus nanoparticles as an adjuvant in a malaria vaccine would result in better protection against the disease when compared to alum, the adjuvant most often used in vaccines.
International Center for Genetic Engineering and Biotechnology (ICGEB), India
Malaria vaccine development has been hindered by the sheer complexity of the parasite and its life cycle, extensive antigenic variation, and a poor understanding of the interaction between P. falciparum (the malaria pathogen) and the human immune system. Despite years of intensive efforts using conventional approaches to vaccine design, there is currently no effective vaccine against malaria therefore new approaches are crucial. The “Plant virus-based nanoparticles as an adjuvant for the development of an efficient and low-cost vaccine against malaria” project aims to use nanoparticles derived from papaya mosaic virus (PapMV-NP) as an adjuvant to develop a novel malaria vaccine that would be safe, efficacious and low-cost.
Jan 2012 — Jul 2013
Related Resources
